β (95% CI) for length of hospital stay across groups of RAR.

β (95% CI) for length of hospital stay across groups of RAR.</p

Kaplan-Meier survival curves for all-cause mortality.

RAR, red blood cell distribution width-to-albumin ratio.</p

The non-linear association between the ASL/ALT ratio and risk of mortality with normal liver function.

Adjusted for all factors in Model 3. The red lines represent the estimated values, and green lines represent their corresponding 95% confidence intervals. (TIF)</p

Subgroup analysis on association of the ASL/ALT ratio with the risk of mortality in patients with an AST/ALT ratio less than 1.80.

Except for the stratification component, each stratification was adjusted for all factors in Model 3.</p

Kaplan–Meier survival curves of critically ill older patients with different AST/ALT ratios.

Kaplan–Meier survival curves of critically ill older patients with different AST/ALT ratios.</p

HR (95% CI) for all-cause mortality across groups of RAR.

HR (95% CI) for all-cause mortality across groups of RAR.</p

Threshold effect analysis of AST/ALT ratio on mortality using two-piecewise linear regression with normal liver function.

Threshold effect analysis of AST/ALT ratio on mortality using two-piecewise linear regression with normal liver function.</p

Threshold effect analysis of AST/ALT ratio on mortality using two-piecewise linear regression.

Threshold effect analysis of AST/ALT ratio on mortality using two-piecewise linear regression.</p

Dose-response relationship between RAR and the risk of all-cause mortality.

Adjusted for all covariates in Model 2. The solid and dashed lines represent the estimated values and 95% confidence intervals. RAR, red blood cell distribution width-to-albumin ratio.</p

Association between AST/ALT ratio and the risk of all-cause mortality in different models using imputed data.

Association between AST/ALT ratio and the risk of all-cause mortality in different models using imputed data.</p